About Signatera and ctDNA
Watch Video
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
The Signatera Approach
Watch Video
-
Seeing beyond the limit: Detect residual disease and assess treatment response
Summary of analytical and clinical data for Signatera™, the first ctDNA assay custom-built for MRD detection and treatment response.
Read Flipbook
-
Introducing Signatera, a personalized, tumor-informed test
Signatera is a new blood test that can identify molecular residual disease, or recurrent cancer, sooner than existing methods, by detecting the presence of ctDNA.
Watch Video
-
Signatera Testing for Circulating Tumor DNA ctDNA Detection
Detect residual disease and recurrence early in colorectal cancer (CRC). How often should Signatera be ordered for CRC patients?
Read Flipbook
-
Signatera and Altera Insurance Coverage and Billing
The first personalized ctDNA test to identify molecular residual disease and optimize treatment decisions.
Read Flipbook
-
When CEA tells us very little
Watch Video
-
Serial ctDNA detection using a personalized, tumor-informed assay in esophageal adenocarcinoma patients following resection
Ococks et al. 2021 Gastroenterology
Read Flipbook
-
BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on pa
Kasi et al. 2021 BMJ Open
Read Flipbook
-
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of- opportunity study
Oliva et al. 2021 Journal for ImmunoTherapy of Cancer
Read Flipbook
-
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizuma
Yang et al. 2021 Nat Commun
Read Flipbook
-
Detecting molecular residual disease with Signatera
Design and analytical validation of SignateraTM, the first ctDNA assay custom-built for detecting MRD and assessing treatment response.
Read Flipbook
-
Signatera Knowing early can make a difference
Signatera is a new cancer surveillance test uniquely personalized for each patient.
Read Flipbook
-
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
Abbosh et al. 2017 Nature
Read Flipbook
-
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients Wi
Christensen et al. 2019 J. Clin. Oncol.
Read Flipbook
-
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
Reinert et al. 2019 JAMA Oncol.
Read Flipbook
-
Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence
Coombes et al. 2019 Clin. Cancer Res.
Read Flipbook
-
Assessment of Molecular Remission in Oligometastatic Esophageal Cancer with a Personalized Circulating Tumor DNA Assay
Einstein et al. 2020 JCO-Precision Oncology.
Read Flipbook
-
Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival
Magbanua et al. 2020 Annals of Oncology
Read Flipbook
-
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer
Jamal-Hanjani et al. 2016 Ann Oncol.
Read Flipbook
-
Loading More...
